Chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) T-cell therapies are promising treatments for a range of cancers, offering hope to patients whose cancers have become refractory to ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
WALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
SINGAPORE and GUANGZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received ...
TScan Therapeutics (TCRX) has been able to report positive results from its phase 1 multi-arm study for the treatment of patients with several types of hematological malignancies such as acute myeloid ...
Immatics is a significant player in T-cell redirecting cancer immunotherapies, with a clinical-stage pipeline showing promising interim results. The company has formed strategic partnerships with ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results